PRINCETON, N.J., and PARIS, Nov. 4, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world’s first and only Self-Apposing™ stent to treat Acute Myocardial Infarction (AMI), will disclose interim results of the APPOSITION III clinical study during a symposium at next week’s TCT (Transcatheter Cardiovascular Therapeutics) 2011 congress in San Francisco. The Breakfast Meeting — “Solving the Sizing Dilemma Using a Self-Apposing™ Stent: STEMI Clinical program in Europe and the U.S.” — will be chaired by two internationally renowned cardiologists: Maurice Buchbinder, M.D., Foundation for Cardiovascular Medicine, La Jolla, CA, and Roxana Mehran, M.D., Mount Sinai Medical Center, New York, N.Y.
The meeting will be held in Room 121 of The Moscone Center beginning at 7:00 a.m. on Tuesday, November 8, 2011.
APPOSITION III is an international “real-life” study that has enrolled more than 600 patients suffering from an STEMI. The trial’s primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.
About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing™ stent adapts to the anatomic changes of the arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.
This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
